Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — Q2 2026 Earnings Presentation
15 slides from Pulse Biosciences's earnings presentation, Aug 6, 2026
Slide 1: Corporate Overview
Corporate Overview August 2026 ©2026 Pulse Biosciences, Inc. All rights reserved. 1
Slide 2: Forward Looking Statements
Forward Looking All statements in this presentation that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s Nanosecond Pulsed Field Ablation (nsPFA) technology and Statements nPulse System to non-thermally clear
Slide 3: Our Mission
Our Mission To build a viable Company that designs, produces, and commercializes next generation therapeutic solutions to improve and extend patients’ lives. We do this with nsPFA and its novel mechanism, regulated cell death. To solve the needs of patients, physicians, and healthcare providers by b
Slide 4: Experienced Technologists, Operators and Clinicians Form a Proven Leadership Team
Experienced Technologists, Operators and Clinicians Form a Proven Leadership Team Paul LaViolette Darrin Uecker Chief Executive Officer Jon Skinner Liane Teplitsky Chief Technology Officer Chief Operating Officer Co-Chairman of the Board Chief Financial Officer Director Established Board Robert (Bob
Slide 5: Financial & Strategic Snapshot
Financial & Strategic Snapshot Balance sheet as of 6/30/2026 • Cash and cash equivalents balance of $101.6mm • No debt • Cash burn: Strategic Capital to support significant clinical opportunities ($18.7mm of cash used in operating activities in 2Q26) ~75% • Raised a total $57.5mm in net proceeds thr
Slide 6: The Nanosecond PFA Advantage – Novel Mechanism, Deeper Ablation
The Nanosecond PFA Advantage – Novel Mechanism, Deeper Ablation A more energy-efficient ablation mechanism, enabling larger, deeper, faster, and safer ablations First Gen Thermal nsPFA Microsecond PFA • High Thermal Energy • Long-duration weak pulses • nsPFA pulses are dramatically • Point-to-point
Slide 7: Pioneering nPulse Technology
Pioneering nPulse Technology Building comprehensive IP to own the nanosecond PFA space 250+ patents covering the complete system from generator to electrodes Generator and System Configuration Methods Across Disease and Conditions Applicators and End Effectors (Disposable Devices) System Accessories
Slide 8: +$3.0B EP Market Opportunity AF Ablation #1 Strategic Priority
EP Market Opportunity +$3.0B U.S. Addressable Annual Market 1 AF Ablation #1 Strategic Priority Market growing at Global Atrial Fibrillation (AF) Drivers of the EP AF Ablation Market 10–15% Disease State: • Drop-in workflow replacement CAGR1 >$8B Electrophysiology Market 2 • Speed + efficiency over
Slide 9: nsPFA Unlocks New Potential in EP
nsPFA Unlocks New Potential in EP LESION Ostial PF Application QUALITY SPEED WORKFLOW EFFICACY • Single • Fewer, faster • Map and ablate – Durability circumferential applications single catheter lesion – • 6-month no rotation • Total PVI speed • Conscious unmatched sedation potential; • 12-month • L
Slide 10: nsPFA FIH Trial: Procedure Time and Freedom AF/AFL/AT Success Rate
nsPFA FIH Trial: Procedure Time and Freedom AF/AFL/AT Success Rate HRS late-breaking data Freedom from Atrial Arrhythmias Parameter April 2026 PATIENT & PROCEDURE OVERVIEW 5S COHORT # of Subjects 141 Procedure Time (mins) 60.2 ± 27.7 12-Month Result: LA Dwell Time (mins) 18.6 ± 13.0 90% freedom from
Slide 11: NANOPULSE-AF IDE Pivotal Study
NANOPULSE-AF IDE Pivotal Study Study Overview Target evaluable enrollment 164 patients Clinical sites Up to 30 First patients enrolled 2Q26 Enrollment target Early Q4 2026 Primary endpoints 6- and 12-months post- ablation procedural success and safety outcomes • Midpoint of enrollment reached with a
Slide 12: Next Gen nPulse Cardiac Catheter – Development Stage
Next Gen nPulse Cardiac Catheter – Development Stage • Enables Single Catheter Workflow: building on the platform to enable Pulmonary Vein Isolation / Posterior Wall Isolation and Mitral Isthmus / Cavotricuspid Isthmus lines with switchable electrodes • Pre-clinical focal data presented in poster at
Slide 13: Multiple High Impact Opportunities Beyond EP
Pulse Biosciences’ nPulse Platform Multiple High Impact Opportunities Beyond EP Status U.S. Procedure Potential • Clinical Validation Cardiac Surgery • NANOCLAMP-AF 24,000 80,000 Prophylactic AF Open Heart Pre-Op Total Open Heart Pivotal Study Enrolling Additional Market AF Treated with Pre-Op AF 4,
Slide 14: Summary and 2026 Priorities
Summary and 2026 Priorities Novel nPulse Energy IP 250 and growing Clinical evidence EP Durability Data • Unique Mechanism of Owned or Licensed • Mounting and superior • 96% procedure success - Action Patents • Paradigm shifting care 12 months • Patent protected • We believe Pulse effectively • 90%
Slide 15: Citations
Citations 1) Clarivate – US EP Market Report. Data on File. 2) Company filings, BofA Global Research. Revenue is BofA estimate from BofA Global Research Market Report. Data on File. 3) Joglar et al J.A.C.C. V O L . 8 3 , N O . 1 , 2 0 2 42023 Guideline for the Diagnosis and Management of Atrial Fibr